Successful long-term triple disease control by ustekinumab in a patient with Behçet's disease, psoriasis and hidradenitis suppurativa
- Ewout M Baerveldt1,2,
- Jasper H Kappen2,
- H Bing Thio1,
- Jan A M van Laar2,
- P Martin van Hagen2,
- Errol P Prens1,2
- 1Department of Dermatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
- 2Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
- Correspondence to Ewout Marinus Baerveldt, Department of Dermatology, Erasmus MC, University Medical Center, PO Box 2040, Rotterdam 3000 CA, The Netherlands; e.baerveldt{at}erasmusmc.nl
- Accepted 21 October 2012
- Published Online First 12 November 2012
Introduction
Behçet's disease (BD) is an auto-inflammatory disorder, characterised by recurrent oral aphtosis, genital ulcers, uveitis and pustular skin lesions.1 Associated cutaneous diseases include Sweet's syndrome,2 erythema nodosum and pyoderma gangrenosum.3 Next to BD, both psoriasis and hidradenitis suppurativa (HS) are clear neutrophilic and interleukin (IL)-17-based diseases, suggesting a pathomechanistic overlap.4–7 However, these diseases rarely co-occur.4 Ustekinumab (anti-p40 mAb), an effective biological treatment for psoriasis, might be effective in BD by interfering with the IL-17 signalling via IL-23 blockage. We present a 39-year-old Caucasian woman in whom the combination of BD, psoriasis and HS was successfully treated with ustekinumab.
Case
At the age of 5, the …
